Sugi Predict

Sugi Predict / Compounds / SCHEMBL751237

SCHEMBL751237

SCHEMBL751237

O=C(O)N1CCC2(CCC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ HSD11B1 P28845 2/20 0.39
▸ CYP2C19 P33261 3/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ CYP2D6 P10635 3/20 0.37
▸ SPR P35270 5/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CTSB P07858 1/20 0.36
▸ CTSS P25774 1/20 0.36
▸ CTSK P43235 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924590 0.95 HSD11B1 (0.42) USP2CYP1A2CYP2C9HSD11B1CYP2C19
SCHEMBL4062010 0.93 HSD11B1 (0.45) USP2CYP1A2CYP2C9HSD11B1CYP2C19
Hydrochloric Acid SCHEMBL8486057 0.93 HSD11B1 (0.41) USP2CYP1A2CYP2C9HSD11B1CYP2C19
SCHEMBL933548 0.90 USP2 (0.41) USP2CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL31607432 0.88 USP2 (0.33) USP2CYP1A2CYP2C9HSD11B1CYP2C19
SCHEMBL15618729 0.86 HSD11B1 (0.47) USP2HSD11B1CYP2C19CYP3A4HIF1A
Hydrochloric Acid SCHEMBL30751767 0.84 HSD11B1 (0.46) USP2HSD11B1CYP2C19CYP3A4HIF1A
SCHEMBL18422376 0.82 GRM5 (0.49) USP2CYP1A2CYP2C9HSD11B1CYP2C19
SCHEMBL484636 0.82 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6
SCHEMBL20564178 0.81 CYP2D6 (0.38) USP2CYP1A2CYP2C9CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 — — US claimed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4731309-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2026-04-29 — — EP disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
EP-4727591-A1 SMARCA2 DEGRADERS AND USES THEREOF Astrazeneca AB (SE) 2026-04-22 — — EP disclosed
US-12599672-B2 KRAS proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2026-04-14 — — US disclosed
US-12590090-B2 Pyrimidine-and nitrogen-containing bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2026-03-31 — — US disclosed
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 — — US disclosed
EP-4631940-A1 COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF Betta Pharmaceuticals Co., Ltd. (CN) 2025-10-15 — — EP disclosed
US-20250270210-A1 BCL-2 Inhibitor BEIGENE, LTD. (KY) 2025-08-28 — — US disclosed
US-8394787-B2 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 — — US disclosed
US-8394787-B2 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-12 — — US disclosed
EP-2520568-A1 Spirocyclic nitriles as inhibitors of protease SANOFI (FR) 2012-11-07 — — EP disclosed
EP-2032535-B1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS SANOFI SA (FR) 2012-08-01 — — EP disclosed
US-20120129830-A1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-24 — — US disclosed
CN-102459232-A 7-aza-spiro [3.5] nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof SANOFI AVENTIS 2012-05-16 — — CN disclosed
EP-2430012-A1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-03-21 — — EP disclosed
WO-2010130945-A1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-11-18 — — WO disclosed
EP-2032535-A1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS Sanofi-Aventis (FR) 2009-03-11 — — EP disclosed
WO-2007137738-A1 SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS SANOFI-AVENTIS (DE) 2007-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 USP2 1713/4885CYP1A2 632/4885CYP2C9 628/4885
US-12599672-B2 KRAS proteolysis targeting chimeras KRAS, HRAS, NRAS USP2 217/4885CYP1A2 4684/4885CYP2C9 4644/4885
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF BCL2, BCL2L2, BCL2L1 USP2 1134/4885CYP1A2 3232/4885CYP2C9 4545/4885
US-20120129830-A1 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF HDAC7, NR3C2, EPOR USP2 4851/4885CYP1A2 822/4885CYP2C9 201/4885
US-20250270210-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 USP2 1111/4885CYP1A2 1655/4885CYP2C9 3172/4885
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof MDM2, TP53, XIAP USP2 334/4885CYP1A2 2501/4885CYP2C9 3105/4885
US-12590090-B2 Pyrimidine-and nitrogen-containing bicyclic compound IRAK1, IRAK4, IRAK2 USP2 3537/4885CYP1A2 3801/4885CYP2C9 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.